University of Sydney, NSW, Australia.
Department of Colorectal Surgery, Royal Prince Alfred Hospital, Sydney, NSW, Australia.
Dis Colon Rectum. 2018 Nov;61(11):1306-1315. doi: 10.1097/DCR.0000000000001213.
Postoperative hemorrhage and thromboembolism are recognized complications following colorectal and abdominal wall surgery, but accurate documentation of their incidence, trends, and outcomes is scant. This is relevant given the increasing number of surgical patients with cardiovascular comorbidity on anticoagulant/antiplatelet therapy.
This study aims to characterize trends in the use of anticoagulant/antiplatelet therapy among patients undergoing major colorectal and abdominal wall surgery within the past decade, and to assess rates of, outcomes following, and risk factors for hemorrhagic and thromboembolic complications.
This is a retrospective cross-sectional study conducted at a single quaternary referral center.
Patients who underwent major colorectal and abdominal wall surgery during three 12-month intervals (2005, 2010, and 2015) were included.
The primary outcomes measured was the rate of complications relating to postoperative hemorrhage or thromboembolism.
One thousand one hundred twenty-six patients underwent major colorectal and abdominal wall surgery (mean age, 61.4 years (SD 16.3); 575 (51.1%) male). Overall, 229 (21.7%) patients were on anticoagulant/antiplatelet agents; there was an increase in the proportion of patients on clopidogrel, dual antiplatelet therapy, and novel oral anticoagulants over the decade. One hundred seven (9.5%) cases were complicated by hemorrhage/thromboembolism. Aspirin (OR, 2.22; 95% CI, 1.38-3.57), warfarin/enoxaparin (OR, 3.10; 95% CI, 1.67-5.77), and dual antiplatelet therapy (OR, 2.99; 95% CI, 1.37-6.53) were most implicated with complications on univariate analysis. Patients with atrial fibrillation (adjusted OR 2.67; 95% CI, 1.47-4.85), ischemic heart disease (adjusted OR, 2.14; 95% CI, 1.04-4.40), and mechanical valves (adjusted OR, 7.40; 95% CI 1.11-49.29) were at increased risk of complications on multivariate analysis. The severity of these events was mainly limited to Clavien-Dindo 1 (n = 37) and 2 (n = 46) complications.
This is a retrospective study with incomplete documentation of blood loss and operative time in the early study period.
One in ten patients incurs hemorrhagic/thromboembolic complications following colorectal and abdominal wall surgery. "High-risk" patients are identifiable, and individualized management of these patients concerning multidisciplinary discussion and critical-care monitoring may help improve outcomes. Prospective studies are required to formalize protocols in these "high-risk" patients. See Video Abstract at http://links.lww.com/DCR/A747.
结直肠和腹壁手术后出血和血栓栓塞是公认的并发症,但对其发病率、趋势和结果的准确记录却很少。鉴于越来越多的心血管合并症患者在抗凝/抗血小板治疗下接受手术,这一点很重要。
本研究旨在描述过去十年中接受主要结直肠和腹壁手术的患者中抗凝/抗血小板治疗的使用趋势,并评估出血和血栓栓塞并发症的发生率、结果和危险因素。
这是一项在单一定点四级转诊中心进行的回顾性横断面研究。
纳入在三个 12 个月时间段(2005 年、2010 年和 2015 年)期间接受主要结直肠和腹壁手术的患者。
主要结局是与术后出血或血栓栓塞相关的并发症发生率。
1126 例患者接受了主要结直肠和腹壁手术(平均年龄 61.4 岁(标准差 16.3);575 例(51.1%)男性)。总体而言,229 例(21.7%)患者正在使用抗凝/抗血小板药物;在过去十年中,使用氯吡格雷、双联抗血小板治疗和新型口服抗凝剂的患者比例有所增加。107 例(9.5%)出现出血/血栓栓塞并发症。阿司匹林(OR,2.22;95%CI,1.38-3.57)、华法林/依诺肝素(OR,3.10;95%CI,1.67-5.77)和双联抗血小板治疗(OR,2.99;95%CI,1.37-6.53)在单变量分析中与并发症最相关。心房颤动(调整后的 OR,2.67;95%CI,1.47-4.85)、缺血性心脏病(调整后的 OR,2.14;95%CI,1.04-4.40)和机械瓣膜(调整后的 OR,7.40;95%CI,1.11-49.29)的患者在多变量分析中发生并发症的风险增加。这些事件的严重程度主要限于 Clavien-Dindo 1(n=37)和 2(n=46)并发症。
这是一项回顾性研究,早期研究期间的失血量和手术时间记录不完整。
每 10 名接受结直肠和腹壁手术的患者中就有 1 名发生出血/血栓栓塞并发症。“高危”患者是可识别的,通过多学科讨论和重症监护监测对这些患者进行个体化管理,可能有助于改善结局。需要前瞻性研究来确定这些“高危”患者的方案。在 http://links.lww.com/DCR/A747 上查看视频摘要。